Search research articles
Contact Us
Filters
Showing results (71-80 of 107) with videos related to
Page
of 11
Sort By:
Frontiers in Oncology
|
February 6, 2024
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, et al.
Frontiers in Oncology
|
June 13, 2022
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey
Gaia Giannone, Daniele Castaldo, Valentina Tuninetti, et al.
Frontiers in Oncology
|
October 2, 2023
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, et al.
Targeted Oncology
|
February 25, 2026
Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer
Camilla Nero, Lisa Salvatore, Simona Duranti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Joyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
The Lancet. Oncology
|
July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Michael Friedlander, Val Gebski, Emma Gibbs, et al.
The International Journal of Biological Markers
|
November 8, 2024
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial
Stefano Indraccolo, Simona Signoriello, Ilaria Piga, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 10, 2024
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study
Valentina Tuninetti, Elisa Virano, Vanda Salutari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial
Domenica Lorusso, Francesco Raspagliesi, Dominique Ronzulli, et al.
Gynecologic Oncology
|
December 10, 2024
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial
Mansoor R Mirza, Line Bjørge, Frederik Marmé, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 107) with videos related to
Sort By:
Page
of 11
Frontiers in Oncology
|
February 6, 2024
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, et al.
Frontiers in Oncology
|
June 13, 2022
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey
Gaia Giannone, Daniele Castaldo, Valentina Tuninetti, et al.
Frontiers in Oncology
|
October 2, 2023
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, et al.
Targeted Oncology
|
February 25, 2026
Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer
Camilla Nero, Lisa Salvatore, Simona Duranti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Joyce F Liu, Nicoletta Colombo, Amit M Oza, et al.
The Lancet. Oncology
|
July 21, 2018
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Michael Friedlander, Val Gebski, Emma Gibbs, et al.
The International Journal of Biological Markers
|
November 8, 2024
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial
Stefano Indraccolo, Simona Signoriello, Ilaria Piga, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 10, 2024
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study
Valentina Tuninetti, Elisa Virano, Vanda Salutari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 5, 2024
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With <i>BRCA</i>-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial
Domenica Lorusso, Francesco Raspagliesi, Dominique Ronzulli, et al.
Gynecologic Oncology
|
December 10, 2024
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial
Mansoor R Mirza, Line Bjørge, Frederik Marmé, et al.
Page
of 11